FIGURE 4.

Enhanced anti‐tumor effects mediated by ABNM@TMZ/OTX. (A) Schematic timeline of the anti‐tumor efficacy study. (B) Bioluminescent signal images of mice bearing orthotopic GL261‐Luc GBM tumor after receiving ABNM@TMZ/OTX, ABNM@TMZ, ABNM@OTX, free TMZ/OTX, free TMZ, or PBS. Mice were intravenously injected at a dose of 5.0 mg TMZ equiv./kg and/or 5.0 mg OTX equiv./kg on days 12, 14, 16, 18, and 20 post‐tumor implantation. (C) Quantified luminescence levels of tumor in mice as treated in b). (D) Mice survival rates. Quantification of number of tumor cells that stained positive for markers of (E) γH2AX, (F) CC3, (G) Ki67, (H) PD‐L1, (I) CD4⁺, and (J) CD8⁺